- Home
- ACCS vs BTAI Comparison
ACCS vs BTAI Comparison
Compare ACCS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | BTAI |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 43.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ACCS | BTAI |
|---|---|---|
| Price | $9.73 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $14.00 | ★ $26.67 |
| AVG Volume (30 Days) | 23.7K | ★ 644.4K |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,646,000.00 | $752,000.00 |
| Revenue This Year | $0.18 | N/A |
| Revenue Next Year | $7.16 | $265.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.30 | N/A |
| 52 Week Low | $7.72 | $1.17 |
| 52 Week High | $13.35 | $8.08 |
Technical Indicators
Market Signals| Indicator | ACCS | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 45.55 |
| Support Level | $9.00 | $1.85 |
| Resistance Level | $11.34 | $2.08 |
| Average True Range (ATR) | 0.75 | 0.15 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 26.49 | 40.51 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.